1. Increasing challenges of inflammatory bowel disease in a Turkish cohort (2006-2016).
- Author
-
Yuksel I, Kilincalp S, Coşkun Y, Akinci H, Karaahmet F, and Hamamci M
- Subjects
- Adalimumab therapeutic use, Adult, Azathioprine therapeutic use, Biological Products therapeutic use, Cigarette Smoking epidemiology, Colitis, Ulcerative epidemiology, Crohn Disease epidemiology, Female, Glucocorticoids therapeutic use, Humans, Inflammatory Bowel Diseases epidemiology, Inflammatory Bowel Diseases therapy, Infliximab therapeutic use, Male, Mesalamine therapeutic use, Methotrexate therapeutic use, Middle Aged, Retrospective Studies, Severity of Illness Index, Sex Distribution, Sulfasalazine therapeutic use, Turkey epidemiology, Young Adult, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Antirheumatic Agents therapeutic use, Colitis, Ulcerative therapy, Crohn Disease therapy, Digestive System Surgical Procedures trends, Gastrointestinal Agents therapeutic use, Hospitalization trends
- Abstract
Background: We aimed to describe the natural course of inflam-matory bowel disease (IBD) in adult Turkish patients during the past decade., Methods: We performed a retrospective investigation in total 508 patients with IBD between 2006 and 2016. The severity of IBD was assessed by the need for hospitalization, biological therapy and surgery. The study consisted of 304 (59.8%) patients with UC, 180 (35.4%) with CD and 24 (4.7%) IBD unclassified patients. The ratio of severe disease for both CD and UC was as follows: hospitalization in 71 (39.4%) and 37 (12.2%), biological therapy received in 20 (11.1%) and 3 (1.0%), and surgery in 23 (12.8%) and 2 (0.7%) respectively. Patients were divided into two groups based on the date of disease onset. Earlier group includes the patients followed-up between 2006-2011 and later group, between 2011-2016. Our results revealed that the proportion of patients receiving biological therapies was significantly higher and the rate of surgery was significantly lower in the later group compared to the earlier group (14.5% to 0%, 9.4 to 23.8, respectively). The hospitalization rate was lower in the later group compared to earlier group but did not reach a significant difference (37.7% to 45.2% respectively)., Conclusions: The course of IBD in Turkish patients appears to be between that of Europe and Asia. In patients with CD, proportion of patients receiving biologic therapy has increased while rate of surgery has decreased., (© Acta Gastro-Enterologica Belgica.)
- Published
- 2018